RxDoctor Payments Data

Frank Procaccino, MD

Gastroenterology · Woodbridge, VANPI 1477658193

Payments from drug & device makers

$4,157in general payments, 2019–2025

Across 168 payments — averaging $24.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$883
  • AbbVie$439
  • Takeda Pharmaceuticals U.S.A., Inc.$397
  • Johnson & Johnson$371
  • Boston Scientific$317
  • Pfizer$217
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$4,12599%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,157 in reported general payments places this provider in the 50th percentile of 473 gastroenterology providers in Virginia.

See all gastroenterology providers in Virginia

Medicare billing

Part B allowed, 2024
$89,592
Medicare patients
364
Services billed
647

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin11$33,540
Mesalamine44$22,295
LinzessLinaclotide16$18,167
Pantoprazole Sodium188$3,665
ClenpiqSod Picosulf/Mag Ox/Citric Ac21$3,485
SutabSod Sulf/Pot Chloride/Mag Sulf17$2,601
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C18$2,502
CholestyramineCholestyramine (With Sugar)18$1,104
Lansoprazole14$1,048
Famotidine67$654
Esomeprazole Magnesium13$310
Omeprazole33$229

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu$883$36,04229 claims
AbbVieLinzess$439$18,16716 claims
Ferring Pharmaceuticals Inc.Clenpiq$95$3,48521 claims
Braintree Laboratories, Inc.Sutab$109$2,60117 claims
SandozLansoprazole$25$1,04814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 473 gastroenterology providers in Virginia.

Other gastroenterology in Woodbridge

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →